The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type
Open accessAbstract
The altered metabolism of tumors has been considered a target for anticancer therapy. However, the relationship between distinct tumor-initiating lesions and anomalies of tumor metabolism in vivo has not been addressed. We report that MYC-induced mouse liver tumors significantly increase both glucose and glutamine catabolism, whereas MET-induced liver tumors use glucose to produce glutamine. Increased glutamine catabolism in MYC-induced liver tumors is associated with decreased levels of glutamine synthetase (Glul) and the switch from Gls2 to Gls1 glutaminase. In contrast to liver tumors, MYC-induced lung tumors display increased expression of both Glul and Gls1 and accumulate glutamine. We also show that inhibition of Gls1 kills cells that overexpress MYC and catabolize glutamine. Our results suggest that the metabolic profiles of tumors are likely to depend on both the genotype and tissue of origin and have implications regarding the design of therapies targeting tumor metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, liver tumors with aberrant overexpression of MYC display enhanced glutamine oxidation and sensitivity to therapies that target glutamine catabolism relative to liver tumors driven by overexpression of MET (196).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“Importantly, inhibiting glutamine entry into the TCA cycle can blunt tumor progression in a MYC-driven cancer model of liver cancer (Xiang et al., 2015; Yuneva et al., 2012) and a MYC-inducible Burkitt lymphoma model (Le et al., 2012; Xiang et al., 2015).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2012
In the citing paper
“MYC has been found to increase mRNA and protein levels of glutamine transporters as well as expression of the enzyme glutaminase, which catalyzes the first step in glutaminolysis (Gao et al., 2009; Wise et al., 2008; Yuneva et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2012
In the citing paper
“Second, although different oncogenes reprogram metabolism in different ways, the tissue in which the oncogene is expressed affects the execution of metabolic reprogramming.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [5]
In the citing paper
“Transgenic MYC induces metabolic changes in both liver tumors and lung tumors but activates glutamine catabolism in lung tumors and glutamine synthesis in liver tumors.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [5]
In the citing paper
“MYC-driven cancer cells exhibit enhanced glutamine utilization accompanied by increased expression of key glutaminolysis enzymes, including GLS1/GLS2 and GLUD1178–180.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [179]
In the citing paper
“furthermore, a similar accumulation of glucose-derived glutamine within the tumor tissue was observed in a mouse model of c-Met-driven liver cancer (Yuneva et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Yuneva et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,346
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C., et al. (2009) · Cell · doi:10.1016/j.cell.2008.11.044 · Cited by 1,798
Wnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,456
Cited by
Sorted by citations
Items 601–638 of 638
Multitracer PET-CT study for characterization of liver mass
Villegas, A. C., Chollet, X. B., Losada, M. M., Garrastachu, P., Bolton, R. C. D., & Lasanta, R. R. (2023) · ANALES RANM · doi:10.32440/ar.2022.139.03.cc01
Bajia, D., Ambe, G. N. N. N., & Derwich, K. (2022) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1622
Biology of cancer: current insights and perspectives
Hakkimane, S. S., & Gaonkar, S. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16034-9.00011-3
Approaches to Study Tumor Metabolism in MicePreprint
Gültekin, Y., Heiden, M. G. V., & Lien, E. C. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041420
Tumor metabolism and anti-tumor immunity
Serganova, I. S., & Zappasodi, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00018-7
The glutamine-aspartate metabolic tradeoff between fast growth and metabolic flexibility
Ortmayr, K., Ringwald, M., Schuhknecht, L., Dubuis, S., Paunossis, E., Blaesi, M., Jehanno, C., Grieder, S. D., Bentires‐Alj, M., Mall, M., et al. (2026) · Genome biology · doi:10.1101/2025.05.12.652188
Tumor Metabolism: Challenges and Future Perspectives
da Silva, E. L., Montenegro, R. C., & Moreira-Nunes, C. A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00761-2_103
Zhang, J., Zhu, X., Hu, L., Yu, L., & Xu, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-03789-1
Lead induces cell-autonomous proliferation and metabolic reprogramming of hepatocytes
Serra, M., Smiriglia, A., Migliore, C., Caddeo, A. M., Lorito, N., Tani, G., Zedda, G., Columbano, A., Perra, A., Giordano, S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08134-6
Additional file 2 of Bayesian kinetic modeling for tracer-based metabolomic data
Zhang, X., Su, Y., Lane, A. N., Stromberg, A. J., Fan, T. W. M., & Wang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26576969
Self-citationKhadka, S., Arthur, K., Barekatain, Y., Behr, E., Washington, M., Ackroyd, J., Crowley, K., Suriyamongkol, P., Lin, Y.-H., Pham, C.-D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14850809
Zhang, L., Su, K., Liu, Q., Li, B., Wang, Y., Cheng, C., Li, Y., Xu, C., Chen, J., Wu, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24540601
Additional file 1 of Bayesian kinetic modeling for tracer-based metabolomic data
Zhang, X., Su, Y., Lane, A. N., Stromberg, A. J., Fan, T. W. M., & Wang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26576966
Self-citationHereditary cancer syndromes linked to oxidative phosphorylation insufficiency
Kaplan, B., Duraj, T., Lee, D. C., & Seyfried, T. N. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0301
Lu, G., Li, Y., Liu, X., & Cui, J. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189529
Charrasse, S., Moussa, D. A., Poquillon, T., Saint-Omer, C., Pastore, M., Reynès, C., Bordignon, B., Roux, P., Frye, R. E., & Aouacheria, A. (2026) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2026.100175 · Cited by 1
A proteomic approach for understanding the metabolic adaptations in non-small cell lung cancer
Martín-Bernabé, A. (2018) · theses.fr (ABES) · doi:10.70675/426e7b40z057az4326z8cfez7da3a5c12c7e
Kaminski, L. (2018) · theses.fr (ABES) · doi:10.70675/7f6ae88bz4f3cz49d3zafcdz8682254b2be3
NMR structural studies of G-quadruplexes nucleic acids from KRAS and their interaction with ligands.
Marquevielle, J. (2019) · theses.fr (ABES) · doi:10.70675/cc9201fez654cz4b3fz9f76z14c65d0d8e86
Rôle du transporteur mitochondrial UCP2 dans la leucémie
Sancerni, T. (2019) · theses.fr (ABES) · doi:10.70675/c0f1a3a3z992az4717zb426z210e51dadf82
Biochemical characterization of mTORC1 regulation by glutamine metabolism
Bodineau, C. (2020) · theses.fr (ABES) · doi:10.70675/9d5aaabdz81bdz4118zb3edze237bdd8dee0
Nuan-Aliman, S. (2021) · theses.fr (ABES) · doi:10.70675/e6d0d159zab42z4fb6zb34fzea69d6185e2a
The anti-tumoral effects of a low protein diet and of the IRE1α signaling
Turtos, A. M. (2022) · theses.fr (ABES) · doi:10.70675/fd90a3e8ze35az42fdzbd0ez966f12ddad22
Fascin-1 as a druggable target in Hepatoblastoma
Dif, L. (2024) · theses.fr (ABES) · doi:10.70675/397187b4z98e4z4886zb816z1a59af68ea71
Zhang, R., Zhang, K., & Li, B. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-04188-5
Campos-Sandoval, J. A., Santos-Jiménez, J. D. L., Márquez, J., & Matés, J. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070850
Self-citationFrom Tissue Specificity to Systemic Cues: Shaping MYC-Driven Tumor Metabolism
Alamoudi, A. A., Mao, Y., Zadra, G., & Labbé, D. P. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-0142
Cai, L., Jendrossek, V., Matschke, J., & Vega-Rubín-de-Celis, S. (2026) · International review of cytology · doi:10.1016/bs.ircmb.2026.07.005
Pan-Cancer Metabolic Landscapes: A Multiomics View
Bai, Y., Chen, Q., & Li, Y. D. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00346
Chakrabarti, P., & Trivedi, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27544-9.00005-2
BindingDB (2021) · UC San Diego · doi:10.7270/q26t0qz0
Chrzanowski, J., Graboń, W., Granica, S., Ludwinek, M., Zdanowicz, A., Pyrzyńska, B., Struga, M., & Cudnoch‐Jędrzejewska, A. (2026) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.1050
Glutamine metabolic interaction network reshapes tumor immunotherapy resistance
Tang, S.-C., Liu, J.-X., Wang, Y., Wang, H., & Lu, L. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.10.001
Metadata
- Authors
- Yuneva, M. O., Fan, T. W. M., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., Matés, J. M., Alonso, F. J., Wang, C., Seo, Y., Chen, X., & Bishop, J. M.
- Affiliations
- University of California, San Francisco (US)
- University of Louisville (US)
- Johns Hopkins University (US)
- Universidad de Málaga (ES)
- Corresponding author
- Yuneva, Mariia O.
- ORCID
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 15
- Issue
- 2
- Pages
- 157-170
- ISSN
- 1550-4131 (ISSN-L)
- PMC
- PMC3282107
- OpenAlex
- W2036659083
- Cited by
- 639
- References
- 64
- Citations by year
- 2026: 17 · 2025: 37 · 2024: 35 · 2023: 41 · 2022: 53 · 2021: 66 · 2020: 43 · 2019: 59 · 2018: 45 · 2017: 63 · 2016: 47 · 2015: 39 · 2014: 42 · 2013: 34 · 2012: 16
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R35CA044338, R01CA118434)
- National Institute of Neurological Disorders and Stroke (R21NS074151)
- National Center for Research Resources (P20RR018733)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- cancer metabolism, c-Myc, MET, glutamine catabolism, glutamine synthetase, glutaminase, GLS1, GLS2, liver tumors, lung cancer, genetic lesions, glutamine accumulation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Citric Acid Cycle, Glucokinase, Glucose, Glutamine, Humans, Immunohistochemistry, Isotope Labeling, Liver Neoplasms, Experimental, Lung Neoplasms, Immunoblotting, Blotting, Western, Proto-Oncogene Proteins c-myc, DNA Primers, Lactic Acid, Proto-Oncogene Proteins c-met, Nuclear Magnetic Resonance, Biomolecular, RNA Interference, Cell Line, Tumor, Mice, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
